Biosimilar insulin lispro shown not inferior to Humalog® in efficacy or safety

(Mary Ann Liebert, Inc./Genetic Engineering News) A study comparing the safety and efficacy of SAR342434, a biosimilar (follow-on form) of insulin lispro-Humalog®, found it to be comparable to that of the brand name drug in patients also using insulin glargine.

Comments
%d bloggers like this: